IRF5 and neoplasm: Indeed, supporting a potential role of CD8+ T‐cells in mediating MCTN‐IRF5 tumor suppression, CD8+ T‐cell depletion has been found to significantly reduce the anti‐tumor activity of IRF5 therapy.[20] By shifting the TME from an immunologically “cold” to “hot” state, MCTN‐IRF5 treatment may improve recognition and rejection of tumor cells by the immune system.[52]